Cargando…

Horses for Courses in the Era of CARs: Advancing CAR T and CAR NK Cell Therapies

The adoptive transfer of allogeneic CAR NK cells holds great promise as an anticancer modality due to the relative ease of manufacturing and genetic modification of NK cells, which translates into affordable pricing. Compared to the pronounced efficacy of CAR T cell therapy in the treatment of B cel...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kulemzin, Sergey, Evsyukov, Igor, Belovezhets, Tatiana, Taranin, Alexander, Gorchakov, Andrey
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8621371/ https://www.ncbi.nlm.nih.gov/pubmed/34834534 http://dx.doi.org/10.3390/jpm11111182

Ejemplares similares

Comparative Pre-Clinical Analysis of CD20-Specific CAR T Cells Encompassing 1F5-, Leu16-, and 2F2-Based Antigen-Recognition Moieties
por: Belovezhets, Tatyana, et al.
Publicado: (2023)

shp-2 gene knockout upregulates CAR-driven cytotoxicity of YT NK cells
por: Subrakova, V.G., et al.
Publicado: (2020)

Design and analysis of stably integrated reporters for inducible transgene expression in human T cells and CAR NK-cell lines
por: Kulemzin, Sergey V., et al.
Publicado: (2019)

VEGFR2-specific FnCAR effectively redirects the cytotoxic activity of T cells and YT NK cells
por: Kulemzin, Sergey V., et al.
Publicado: (2018)

CAR race to cancer immunotherapy: from CAR T, CAR NK to CAR macrophage therapy
por: Pan, Kevin, et al.
Publicado: (2022)

Advancements in CAR-NK therapy: lessons to be learned from CAR-T therapy
por: Kilgour, Marisa K., et al.
Publicado: (2023)

Current status and perspective of CAR-T and CAR-NK cell therapy trials in Germany
por: Albinger, Nawid, et al.
Publicado: (2021)

The Race of CAR Therapies: CAR-NK Cells for Fighting B-Cell Hematological Cancers
por: Herrera, Lara, et al.
Publicado: (2021)

Humanized Mice Are Precious Tools for Preclinical Evaluation of CAR T and CAR NK Cell Therapies
por: Mhaidly, Rana, et al.
Publicado: (2020)

Importance of T, NK, CAR T and CAR NK Cell Metabolic Fitness for Effective Anti-Cancer Therapy: A Continuous Learning Process Allowing the Optimization of T, NK and CAR-Based Anti-Cancer Therapies
por: Krug, Adrien, et al.
Publicado: (2021)

CAR NK Cell Therapy for T Follicular Helper Cells
por: King, Cecile
Publicado: (2020)

Biomarkers as targets for CAR-T/NK cell therapy in AML
por: Shao, Ruonan, et al.
Publicado: (2023)

Outsmarting trogocytosis to boost CAR NK/T cell therapy
por: Ramezani, Faezeh, et al.
Publicado: (2023)

Engineering the next generation of CAR-NK immunotherapies
por: Biederstädt, Alexander, et al.
Publicado: (2021)

Real-World Outcome in the pre-CAR-T Era of Myeloma Patients Qualifying for CAR-T Cell Therapy
por: Brechbühl, Simon, et al.
Publicado: (2021)

From CAR-T Cells to CAR-NK Cells: A Developing Immunotherapy Method for Hematological Malignancies
por: Lu, Hui, et al.
Publicado: (2021)

China enters CAR-T cell therapy era
por: Cao, Xin, et al.
Publicado: (2021)

Seatbelts in CAR therapy: How Safe Are CARS?
por: Minagawa, Kentaro, et al.
Publicado: (2015)

Current Progress of CAR-NK Therapy in Cancer Treatment
por: Pang, Zhaojun, et al.
Publicado: (2022)

Engineering NK Cells for CAR Therapy—Recent Advances in Gene Transfer Methodology
por: Schmidt, Paula, et al.
Publicado: (2021)

The development of CAR design for tumor CAR-T cell therapy
por: Xu, Dandan, et al.
Publicado: (2018)

CAR-NK Cells in the Treatment of Solid Tumors
por: Wrona, Ewa, et al.
Publicado: (2021)

Taking Lessons from CAR-T Cells and Going Beyond: Tailoring Design and Signaling for CAR-NK Cells in Cancer Therapy
por: Ruppel, Katharina Eva, et al.
Publicado: (2022)

CAR‐NK cells: the next wave of cellular therapy for cancer
por: Daher, May, et al.
Publicado: (2021)

Overcoming tumor resistance mechanisms in CAR-NK cell therapy
por: Valeri, Antonio, et al.
Publicado: (2022)

Preclinical and clinical studies of CAR-NK-cell therapies for malignancies
por: Li, Hongwen, et al.
Publicado: (2022)

CAR-NK cell therapy for glioblastoma: what to do next?
por: Xiong, Qi, et al.
Publicado: (2023)

Use of Cell and Genome Modification Technologies to Generate Improved “Off-the-Shelf” CAR T and CAR NK Cells
por: Morgan, Michael A., et al.
Publicado: (2020)

Current Perspectives on “Off-The-Shelf” Allogeneic NK and CAR-NK Cell Therapies
por: Heipertz, Erica L., et al.
Publicado: (2021)

Engineering switchable and programmable universal CARs for CAR T therapy
por: Liu, Delong, et al.
Publicado: (2019)

Advances in Universal CAR-T Cell Therapy
por: Lin, Haolong, et al.
Publicado: (2021)

CARs and Drugs: Pharmacological Ways of Boosting CAR-T-Cell Therapy
por: Harrer, Dennis Christoph, et al.
Publicado: (2023)

CAR(+) and CAR(−) T cells share a differentiation trajectory into an NK-like subset after CD19 CAR T cell infusion in patients with B cell malignancies
por: Louie, Raymond Hall Yip, et al.
Publicado: (2023)

Conventional CARs versus modular CARs
por: Feldmann, Anja, et al.
Publicado: (2019)

CAR-T Cell Therapy
por: Ahmad, Aamir
Publicado: (2020)

Abstract 2 Development of CAR-NK Cell Therapy for Hematologic Malignancies
por: Stoltzman, Carrie, et al.
Publicado: (2022)

CAR-NK Cells: A Chimeric Hope or a Promising Therapy?
por: Sabbah, Mohamad, et al.
Publicado: (2022)

CAR-NK Cell: A New Paradigm in Tumor Immunotherapy
por: Marofi, Faroogh, et al.
Publicado: (2021)

Universal CARs, universal T cells, and universal CAR T cells
por: Zhao, Juanjuan, et al.
Publicado: (2018)

Motor Cars for Doctors: Cars Suitable for Practitioners
Publicado: (1906)

Cannot write session to /tmp/vufind_sessions/sess_fr1f4mit42o59t3klifpco5vcp